BR112018006953A2 - anticorpos com estabilidade melhorada para digestão intestinal - Google Patents
anticorpos com estabilidade melhorada para digestão intestinalInfo
- Publication number
- BR112018006953A2 BR112018006953A2 BR112018006953A BR112018006953A BR112018006953A2 BR 112018006953 A2 BR112018006953 A2 BR 112018006953A2 BR 112018006953 A BR112018006953 A BR 112018006953A BR 112018006953 A BR112018006953 A BR 112018006953A BR 112018006953 A2 BR112018006953 A2 BR 112018006953A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- intestinal digestion
- present
- improved stability
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237270P | 2015-10-05 | 2015-10-05 | |
| PCT/US2016/054304 WO2017062253A2 (en) | 2015-10-05 | 2016-09-29 | Antibodies with improved stability to intestinal digestion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018006953A2 true BR112018006953A2 (pt) | 2018-10-23 |
Family
ID=58488349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018006953A BR112018006953A2 (pt) | 2015-10-05 | 2016-09-29 | anticorpos com estabilidade melhorada para digestão intestinal |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11891440B2 (https=) |
| EP (1) | EP3359190A4 (https=) |
| JP (2) | JP7235287B2 (https=) |
| AU (2) | AU2016335912B2 (https=) |
| BR (1) | BR112018006953A2 (https=) |
| CA (1) | CA3039177A1 (https=) |
| IL (1) | IL258496A (https=) |
| WO (1) | WO2017062253A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230125085A (ko) * | 2016-08-15 | 2023-08-28 | 국립대학법인 홋가이도 다이가쿠 | 항pd-l1 항체 |
| WO2020123798A1 (en) * | 2018-12-12 | 2020-06-18 | President And Fellows Of Harvard College | Bovine versions of fcmbl for the detection and treatment of bovine microbial infections |
| JP2023551194A (ja) * | 2020-11-20 | 2023-12-07 | ゾエティス・サービシーズ・エルエルシー | ウシ科動物抗体バリアント |
| EP4695308A1 (en) * | 2023-09-14 | 2026-02-18 | Invitrogen BioServices India Private Limited | Engineered antibodies and uses thereof |
| CN120209146A (zh) * | 2025-03-31 | 2025-06-27 | 上海百英生物科技股份有限公司 | 一种包含非天然氨基酸修饰的Claudin 6抗体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US8647626B2 (en) * | 2007-10-02 | 2014-02-11 | Avaxia Biologics, Incorporated | Compositions comprising TNF-specific antibodies for oral delivery |
| EP2725035A1 (en) * | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| ES2622102T3 (es) * | 2009-10-29 | 2017-07-05 | Janssen Biotech, Inc. | Variantes de anticuerpo de glicosilación |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| TW201233686A (en) * | 2010-12-27 | 2012-08-16 | Japan Health Science Found | Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same |
| CN103917555A (zh) * | 2011-08-01 | 2014-07-09 | 艾瓦夏生物制剂公司 | 人tnf特异性的牛科动物多克隆抗体 |
| AU2017313495B2 (en) * | 2016-08-15 | 2023-09-07 | Fuso Pharmaceutical Industries, Ltd. | Anti-PD-1 antibody |
-
2016
- 2016-09-29 US US15/765,958 patent/US11891440B2/en active Active
- 2016-09-29 AU AU2016335912A patent/AU2016335912B2/en not_active Ceased
- 2016-09-29 BR BR112018006953A patent/BR112018006953A2/pt not_active Application Discontinuation
- 2016-09-29 WO PCT/US2016/054304 patent/WO2017062253A2/en not_active Ceased
- 2016-09-29 JP JP2018536696A patent/JP7235287B2/ja active Active
- 2016-09-29 EP EP16854106.8A patent/EP3359190A4/en not_active Withdrawn
- 2016-09-29 CA CA3039177A patent/CA3039177A1/en active Pending
-
2018
- 2018-04-04 IL IL258496A patent/IL258496A/en unknown
-
2022
- 2022-09-29 JP JP2022156598A patent/JP2022185053A/ja active Pending
-
2023
- 2023-06-29 US US18/344,311 patent/US20240067715A1/en not_active Abandoned
- 2023-08-16 AU AU2023216791A patent/AU2023216791A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022185053A (ja) | 2022-12-13 |
| JP7235287B2 (ja) | 2023-03-08 |
| US20240067715A1 (en) | 2024-02-29 |
| EP3359190A4 (en) | 2020-05-06 |
| AU2016335912A1 (en) | 2018-05-24 |
| JP2018537117A (ja) | 2018-12-20 |
| EP3359190A2 (en) | 2018-08-15 |
| WO2017062253A3 (en) | 2017-05-11 |
| IL258496A (en) | 2018-05-31 |
| AU2023216791A1 (en) | 2023-09-07 |
| AU2016335912B2 (en) | 2023-08-31 |
| CA3039177A1 (en) | 2017-04-13 |
| US11891440B2 (en) | 2024-02-06 |
| WO2017062253A2 (en) | 2017-04-13 |
| US20220073602A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018006953A2 (pt) | anticorpos com estabilidade melhorada para digestão intestinal | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| BR112019012071A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de integrina | |
| EA201791702A1 (ru) | Терапевтические средства на основе гликанов и связанные с ними способы | |
| TN2019000187A1 (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| BR112015014372A2 (pt) | inibidores de autotaxina | |
| BR112019011702A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível | |
| EP3363458A3 (en) | A peptide | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
| BR112017025664A2 (pt) | composições e métodos para aumentar a neurogênese em animais | |
| IL284733A (en) | Pharmaceutical delivery compositions and uses thereof | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| BR112021024938A2 (pt) | Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso | |
| ZA202107587B (en) | Aqueous pharmaceutical compositions of an anti-il17a antibody and use thereof | |
| EP3509573A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | |
| EP3840735C0 (en) | CAPSULE DEVICE FOR ADMINISTERING AN ACTIVE INGREDIENT TO THE DIGESTIVE TRACT | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| EP3313379A4 (en) | ORAL PHARMACEUTICAL FORM FOR THE DISTRIBUTION OF A PEPTIDE AND / OR PROTEIN | |
| BR112015019264A8 (pt) | cápsulas para o tratamento de helicobacter pylori e seu uso". | |
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| MA55568A (fr) | Compositions pharmaceutiques orodispersibles d'apixaban |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |